Juliet Gray

Dr. Juliet Gray is an Associate Professor in Paediatric Oncology at the Cancer Immunology Centre, University of Southampton. She leads a translational research group focused on novel antibody immunotherapies for neuroblastoma, including preclinical evaluation of novel combinational therapies as well as early phase clinical trials.

Dr. Gray’s specific research interests are in targeting anti-GD2 monoclonal antibodies, and immunomodulatory antibodies such as those targeting PD-1. She has developed the laboratory support and immune endpoint assays within the Southampton Experimental Cancer Medicine Centre, required to support early phase immunotherapy studies.

Dr. Gray was the UK Chief Investigator and member of the Trial Steering Committee for the SIOPEN Long Term Infusion of ch14.18 (anti-GD2) monoclonal antibody in children with relapsed/refractory neuroblastoma, and is the Chief Investigator of the first ever transatlantic neuroblastoma study to open in the UK – a multi-centre Phase I trial of 131-I mIBG therapy, Nivolumab and ch14.18/CHO in children with relapsed/refractory neuroblastoma.

Dr. Gray plays a key role in both UK and European neuroblastoma research; and is a member of the UK NCRI Childhood Cancer and Leukaemia Neuroblastoma subgroup, executive member of the European Neuroblastoma Research Network (SIOPEN), and member of the SIOPEN Immunotherapy Committee.